Novartis Buys US Drugmaker for Up To $665 Million

The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.

By | November 23, 2016

WIKIMEDIA, JERICHO In an up-to-$665 million deal, Novartis is set to acquire Selexys Pharmaceuticals, an inflammatory and thrombotic disease–focused biotech based in Oklahoma City, whose lead candidate, an antibody for the treatment of sickle cell disease–associated pain, has shown promise in a Phase 2 clinical trial, the firms announced this week (November 21). In 2012, Novartis obtained the exclusive right to acquire Selexys and its antibody drug candidate, “SelG1.”

“The acquisition of Selexys by Novartis represents an important step in the continued development of SelG1, a novel, potential first-in-class therapy for patients with this underserved life-threatening disease,” Scott Rollins, former president and chief executive officer of Selexys, said in the statement.

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

  3. Government Nixes Teaching Evolution in Turkish Schools
  4. Athletes’ Microbiomes Differ from Nonathletes